CytomX Therapeutics (CTMX) Projected to Post Quarterly Earnings on Thursday

CytomX Therapeutics (NASDAQ:CTMX) is expected to post its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to announce earnings of ($0.09) per share and revenue of $10.38 million for the quarter. Individuals can check the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 5, 2026 at 5:00 PM ET.

CytomX Therapeutics (NASDAQ:CTMX) last issued its earnings results on Thursday, August 6th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.01). CytomX Therapeutics had a negative net margin of 435.21% and a negative return on equity of 38.46%. The business had revenue of $1.42 million for the quarter, compared to the consensus estimate of $12.39 million. On average, analysts expect CytomX Therapeutics to post ($0.40) EPS for the current fiscal year and ($0.52) EPS for the next fiscal year.

CytomX Therapeutics Price Performance

Shares of CTMX stock opened at $2.18 on Wednesday. The company’s fifty day simple moving average is $2.78 and its two-hundred day simple moving average is $3.85. CytomX Therapeutics has a 1 year low of $2.14 and a 1 year high of $8.21.

Analyst Ratings Changes

Several brokerages have recently weighed in on CTMX. JPMorgan Chase & Co. reduced their price target on CytomX Therapeutics from $12.00 to $11.00 and set an “overweight” rating for the company in a research report on Thursday, August 13th. Guggenheim dropped their price objective on CytomX Therapeutics from $15.00 to $14.00 and set a “buy” rating on the stock in a report on Monday, August 10th. Weiss Ratings restated a “sell (d)” rating on shares of CytomX Therapeutics in a research note on Friday, September 11th. Zacks Research lowered CytomX Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 19th. Finally, Wall Street Zen cut CytomX Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, August 23rd. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, CytomX Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $11.90.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing cancer medicines designed to be activated selectively within the tumor microenvironment. The company’s approach is intended to improve the precision of treatment by limiting activity in healthy tissues while enabling therapeutic effects at tumor sites.

CytomX’s research is based on its Probody therapeutic platform, which uses molecular masking and tumor-associated protease activity to conditionally activate antibody-based medicines.